Notice: file_put_contents(): Write of 8531 bytes failed with errno=28 No space left on device in /var/www/tg-me/post.php on line 50
Readhub | Telegram Webview: readhub_cn/254219 -
Telegram Group & Telegram Channel
智飞生物双价痢疾结合疫苗将于孟加拉国启动Ⅲ期临床试验

智飞生物子公司自主研发的双价痢疾结合疫苗即将在孟加拉国启动Ⅲ期临床试验,该疫苗用于预防福氏志贺菌和宋内氏志贺菌引起的细菌性痢疾,是国际首个可同时预防这两种志贺菌感染的疫苗,目前全球尚无同类产品获批上市。细菌性痢疾为全球性公共卫生问题,每年发病人数达1.647亿,主要由福氏和宋内氏志贺菌引起。智飞生物致力于推动更多优质疫苗上市,守护人类健康。

媒体报道
智飞生物四价流脑结合疫苗获得Ⅲ期临床试验总结报告 医药魔方
智飞生物:四价流脑结合疫苗获得Ⅲ期临床试验总结报告 界面
智飞生物双价痢疾结合疫苗将于孟加拉国启动Ⅲ期临床试验 医药魔方

事件追踪
2024-10-09 智飞生物:四价流感病毒裂解疫苗(儿童型)申请生产注册获得受理
2024-08-21 智飞生物26价肺炎球菌结合疫苗启动Ⅰ/Ⅱ期临床试验

#热门话题



tg-me.com/readhub_cn/254219
Create:
Last Update:

智飞生物双价痢疾结合疫苗将于孟加拉国启动Ⅲ期临床试验

智飞生物子公司自主研发的双价痢疾结合疫苗即将在孟加拉国启动Ⅲ期临床试验,该疫苗用于预防福氏志贺菌和宋内氏志贺菌引起的细菌性痢疾,是国际首个可同时预防这两种志贺菌感染的疫苗,目前全球尚无同类产品获批上市。细菌性痢疾为全球性公共卫生问题,每年发病人数达1.647亿,主要由福氏和宋内氏志贺菌引起。智飞生物致力于推动更多优质疫苗上市,守护人类健康。

媒体报道
智飞生物四价流脑结合疫苗获得Ⅲ期临床试验总结报告 医药魔方
智飞生物:四价流脑结合疫苗获得Ⅲ期临床试验总结报告 界面
智飞生物双价痢疾结合疫苗将于孟加拉国启动Ⅲ期临床试验 医药魔方

事件追踪
2024-10-09 智飞生物:四价流感病毒裂解疫苗(儿童型)申请生产注册获得受理
2024-08-21 智飞生物26价肺炎球菌结合疫苗启动Ⅰ/Ⅱ期临床试验

#热门话题

BY Readhub


Warning: Undefined variable $i in /var/www/tg-me/post.php on line 283

Share with your friend now:
tg-me.com/readhub_cn/254219

View MORE
Open in Telegram


Readhub Telegram | DID YOU KNOW?

Date: |

Launched in 2013, Telegram allows users to broadcast messages to a following via “channels”, or create public and private groups that are simple for others to access. Users can also send and receive large data files, including text and zip files, directly via the app.The platform said it has more than 500m active users, and topped 1bn downloads in August, according to data from SensorTower.

Importantly, that investor viewpoint is not new. It cycles in when conditions are right (and vice versa). It also brings the ineffective warnings of an overpriced market with it.Looking toward a good 2022 stock market, there is no apparent reason to expect these issues to change.

Readhub from ar


Telegram Readhub
FROM USA